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Su_numy We have examined a series of human colorectal adenomas, carcinomas and cell lines derived from
human colorectal cancer for loss of heterozygosity (LOH) on chromosome lq22-23 by polymerase chain
reaction (PCR) amplification of a microsatellite polymorphism of the dopamine D2 receptor (DRD2) locus.
LOH was demonstrated in 5 30 (16.7%) adenomas and 23/68 (33.8%) carcinomas. Only 2,'20 (10%) cell lines
showed homozygosity which could potentially be as a consequence of LOH. This moderate level of loss in the
tumour samples was probably not an underestimation as a result of excessive stromal contamination because
high rates (68-77%) have been detected in the same samples on chromosomes 17 and 18. In contrast to a
previous report. LOH in carcinomas at 1I q22-23 occurred at a lower frequency and was not associated with
Dukes' stage, degree of differentiation, mucin production or the location of the cancer. However, a significant
association was found between LOH on chromosome 11 and chromosome 14. Thus, inactivation of any
putative tumour-suppressor gene at lq22-23 by LOH is not a very common event in the development of
colorectal tumours. but may be biologically significant if accompanied by chromosome 14 deletions.
Colorectal carcinogenesis is a multistep process involving
both the activation of proto-oncogenes and the inactivation
of tumour-suppressor genes. The current model originally
described by Fearon and Vogelstein (1990) identifies four
main mutations, which include ras oncogene point mutations
and allelic deletions and point mutations of the tumour-
suppressor genes APC, p53 and DCC on chromosomes 5, 17
and 18 respectively. However, some adenomas have been
identified which contain all four of these mutations but have
not progressed to carcinoma, suggesting that additional
genetic events are necessary for the transition from adenoma
to carcinoma. In addition, frequent LOH has also been
reported in colorectal tumours on chromosome 8 (Fujiwara
et al., 1993) and 14 (Young et al., 1993).
Tumour-suppressor genes usually function in a recessive
manner and therefore require both copies to be inactivated
for tumour progression to occur (Knudson et al., 1971). Loss
of an allele is a common mechanism of inactivation, and
hence detection of LOH is an important tool in identifying
regions of the genome which may contain a tumour-sup-
pressor gene. Chromosome 11 was considered a candidate for
harbouring a tumour-suppressor gene because of cytogenetic
analyses on colorectal cancers which have found frequent
deletions in the long arm of chromosome 11 (Muleris et al.,
1990; Konstantinova et al., 1991). In addition, a recent study
of 39 human colorectal carcinomas by Keldysh et al. (1993)
identified 1iq deletions in 59% by restriction fragment length
polymorphism (RFLP) and cytogenetic analyses. The
smallest region of overlap (SRO) of these deletions was
mapped to the region of 11q22-23. We have examined 101
colorectal cancers for allelic loss at the DRD2 gene located at
1 1q22-23 in order to evaluate the findings of Keldysh et al.
in a larger series.
Materias and methods
Patient samples and cell lines
Samples were obtained from 126 patients with sporadic col-
onic neoplasia during surgery or colonoscopy and purified
macroscopically by a pathologist. Germline samples for each
patient were obtained from normal colonic mucosa or
peripheral blood leukocytes.
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The following cell lines were used in this study: HT-29,
CaCo-2, Lisp-i, SW480, SW620, LIM1215, LIM1863,
LIM2405, LIM2412, LIM1899, LIM2099, HCT-116, T84,
LS174-T, KM12-SM, LS1034, LS41IN, SW116, LS513 and
LoVo. Cell lines were cultured in RPMI-1640 medium or
Dulbecco's modified Eagle medium (Gibco), supplemented
with 10% fetal calf serum. DNA extraction from both
patient material and cell lines was essentially as described by
Miller et al. (1988).
PCR amplification reactions
PCR amplification of the TG microsatellite in the DRD2
locus was performed using the primers 509 and 419 (Hauge
et al., 1993) and produced a four-allele polymorphism with
bands of 80, 82, 84 or 86 bp in size. In a total volume of
10 il, 50 ng of genomic template DNA was amplified with
0.5 gIM primers, 1.5 mM magnesium chloride (Promega),
1 x PCR buffer (Promega), 200gtM dTTP, dGTP, dCTP, 0.5
units of Taq polymerase (Promega), and 0.1 L of [35SIdATP
(12.5 mCi, Amersham). Amplification reactions were carried
out in an ITCIOO thermal cycler (Bartelt Industries, Mel-
bourne, Australia) as follows. An initial 4 min denaturation
at 94°C was followed by 25 cycles of 40s at 94C, 30 s at
56°C and 20 s at 74°C, with a 3 min final extension at 74C.
PCR products were electrophoresed on a 5% polyacrylamide
gel for 2 h. The gels were fixed, dried, then exposed to either
Kodak X-OMAT film or a phosphor screen. This screen was
scanned by the phosphorimager (Molecular Dynamics) after
a 6-12 h exposure, and the autoradiographs were scanned by
a densitometer (Molecular Dynamics) after a 24 h exposure.
Resultant images were analysed using the computer software
ImageQuant.
Analysis ofLOH
Analysis of informative cases for LOH was accomplished by
quantitating the density of bands produced by [35S]dATP
incorporation during PCR amplification. LOH was calcu-
lated by a modification of the method by Solomon et al.
(1987), in which a ratio of allelic imbalance of less than 0.75
or greater than 1.25 was considered to show LOH. Analysis
of 2 x 2 tables was carried out using a two-tailed Fisher
exact test, and trend analysis performed by the Wilcoxon's
rank-sum test. The Mantel-Haenszel inference was used to
stratify for stage.
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Results
Of the 126 patients analysed by PCR for microsatellite
polymorphism at the DRD2 locus at llq22-23, 84 (66.7%)
were informative. From these 84 informative patients, 101
samples (consisting of 30 adenomas, 68 carcinomas and three
metastases) were analysed for LOH, which was demonstrated
in a total of 30 101 (29.7%) informative lesions. Of 68 car-
cinomas tested, 23 (33.8%) showed allelic loss. This is
significantly lower than the frequency of 1 lq cytogenetic
deletions (P= 0.0239) and the combined frequency of
cytogenetic deletions and RFLP allelic losses (P= 0.0151)
reported by Keldysh et al. (1993). However, our low fre-
quency of LOH does not differ significantly (P= 0.0778)
from the figures that Keldysh et al. obtained by RFLP
analysis alone.
Of 30 adenomas tested, five (16.7%) showed allelic loss.
The mean size of adenomas not showing LOH was 1.1 cm,
while that of adenomas showing LOH was slightly less than
1 cm. Of the nine patients from whom both an adenoma and
a carcinoma were tested, one showed LOH in both the
adenoma and carcinoma, two showed LOH in the carcinoma
only, and the remaining six had no LOH in either the
carcinoma or the adenoma. Metastatic tissue was examined
from three patients and two showed allelic loss. For one of
these two, primary carcinoma as well as metastatic tissue was
available, and this also showed LOH. The one metastatic
sample which showed no LOH had no loss in the primary
tumour either. Of the 34 samples showing LOH, the larger
allele was lost in 58% of cases, while the smaller was lost in
42% of cases. This is not significantly different from the
expected ratio of 1:1 (P = 0.62) and indicates that the LOH
was not an artifact caused by incomplete amplification of the
larger alleles (Figure 1).
A summary of the histological and clinical features of the
carcinomas tested is given in Table I. No significant associa-
tions were found between LOH on chromosome 11 and
location (P = 0.997), Dukes' stage (P = 0.881), differentiation
status of the tumour (P = 0.922) or sex of the patient











Flgwe 1 LOH at the DRD2 locus in colonic tumours showing No loss
loss of the 80 bp allele in the tumour of patient B.K. and of the
86 bp allele in the tumour of patient D.P.
Table I Histological and clinical characteristics of
examined for LOH on llq
allelic loss was demonstrated was 68.8 years compared with
68.3 years in those who did not exhibit LOH. Only one
carcinoma with LOH was mucin producing. A further three
mucin-producing tumours did not show LOH.
K-ras mutation and LOH data for nine other chromosome
arms (1p, lq, 5q, 8p, 14q, 17p, 17q, 18q, 22q) were available
for these tumours (Young et al., 1993; J. Young et al.
submitted). There was no significant association between K-
ras mutation or LOH at any of these sites and chromosome
11 (data not shown), with the exception of chromosome 14
(Young et al., 1993). LOH on chromosomes 11 and 14 in
carcinomas (Table II) was significantly associated
(P = 0.0007), and this association was maintained when the
tumours were stratified for Dukes' stage (P = 0.028).
Twenty cell lines established from human colorectal
cancers were also analysed at the DRD2 locus. While cor-
responding germ-line material was not available for
comparison, 18/20 (90%) were heterozygous, therefore a
maximum of 2/20 (10%) could have undergone allelic loss at
this locus.
Discs~
A high rate of LOH in the region of chromosome 11 would
suggest the existence of a putative tumour-suppressor gene
which may be inactivated in human colorectal carcinoma.
The rate of LOH on lq in colorectal carcinomas found in
our study (33.8%) was similar to the cytogenetic data found
previously by Muleris et al. (1990), who found rear-
rangements in 28% of colorectal cancers examined. In con-
trast, Vogelstein et al. (1989) found LOH at the DllS144
locus at 1lq22.3-23.3 in only 15% of tumours. Moreover, of
20 colorectal cell lines examined in this study only 10% were
homozygous at this locus. Even if this was not due to natural
homozygosity and had occurred through deletion of a second
copy of a gene, 10% is a very low rate of LOH. These low
rates of 10-33.8% LOH are somewhat inconsistent with
those recently reported by Keldysh et al. (1993), who
observed cytogenetic deletions or LOH at 1 lq in 23/39 (59%)
of tumours. There are at least two possible explanations for
the lower incidence of LOH in our study. Firstly, we
examined a larger sample consisting of 101 informative cases
instead of 39, and so the lower frequency that we report is
probably more accurate. Secondly, our sample population
was chosen completely randomly, with no enrichment of the
sample population by prior knowledge of llq chromosomal
aberrations, whereas the sample that Keldysh et al. used
included some tumours which were known by cytogenetic










Location Dukes' stage Differentuation
Right Left A B C D Poor Moderate Well
+ LOH 7 14 2 7 9 4 3 16 1
-LOH 15 29 4 24 10 7 7 35 2
Total 22 43 6 31 19 11 10 51 3
LOH (%) 32 33 33 23 46 36 30 51 33CHROMOSOME 11 LOH IN COLORECTAL CANCER 397
analyses to have 1Iq abnormalities. These explanations are
consistent with the fact that our results are not significantly
different to the RFLP analysis that Keldysh et al. performed,
whereas if the cytogenetic analyses were taken into account,
significant differences were obtained. Keldysh et al. found
non-significant associations between llq LOH and (1) rectal
location, (2) Dukes' A stage, (3) mucin production and (4)
well-differentiated carcinomas. None of these associations
was substantiated in this study. Keldysh et al. did not
examine the DRD2 locus itself, but it is located within the
SRO (Eubanks et al., 1992) that they defined by analysis of
partial deletions. Keldysh et al. used Southern analysis of an
RFLP to detect LOH, while we used PCR of a microsatellite.
However, a direct comparison of these techniques in ten
tumours of this sample for detecting LOH at p53 found them
to give the same results (B. Leggett et al., submitted). This is
substantiated by the fact that the LOH rate at the p53 locus
with a RFLP of low heterozygosity was 7/10 (70%) com-
pared with 45/66 (68%) using a (CA). repeat. There are now
numerous reports of the use of microsatellite markers to
detect LOH (Futreal et al., 1992; Chenevix-Trench et al.,
1993; Linnenbach et al., 1993). The major advantages are in
saving of time and DNA, the high informativeness of the
markers and the ability to use formalin-fixed material.
To confirm that contamination by normal mucosa did not
result in an underestimation of the degree of allelic loss at
this locus, the level of LOH on 1 lq was also shown to be low
compared with the rate of 68% (45/66) observed in these
carcinomas by PCR at the p53 locus, and 77% at the DCC
locus by RFLP. However, 33.8% is probably above back-
ground (8-23% in this series) and, interestingly, does occur
in 17% of adenomas in which the background rate is even
lower. This level of LOH in adenomas suggests that inactiva-
tion of a gene at 1 Iq22-23 may be an important early
change in a subset of colon tumours. Similar frequencies of
mutations in adenomas were observed at the 12th codon of
K-ras in this sample (J. Young et al., submitted), and in 17p
and 18q class II adenomas by Vogelstein et al. (1988).
The possibility that a tumour-suppressor gene inactivated
in colorectal cancer exists on 1 1q cannot be discounted
simply because of the moderately low LOH rate observed in
this study. Tanaka et al. (1991) found that human colon
carcinoma cells into which a normal copy of chromosome 11
had been transferred exhibited a reduced tumour growth rate
compared with that seen in the parental cells, although
tumorigenicity was not reversed. This suggests that there may
be a gene on chromosome 11 which has some effect on the
rate of cell growth. Our data indicate that inactivation of a
gene at 1lq22-23 by LOH is not a very common event in
the development of colorectal tumours but that it is
significantly associated with LOH on chromosome 14. This
indicates that chromosome 11 deletions may be important if
they occur in combination with losses on chromosome 14.
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